News | September 10, 2024
Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Subscribe To Our Newsletter & Stay Updated
